Table 1.
SARS-CoV-2 testing and cycle threshold (Ct) values over a 154-day timeframe
| Date | Test result | Source of specimen | SARS-CoV-2 cycle threshold (Ct) |
Testing platform |
| Day 1: 2 April 2020 | Positive | Nasopharynx-oropharynx | ORF1a 15.49, E 16.08 | Mayo Clinic Roche C6800* |
| Day 8: 9 April 2020 | Positive | Nasopharynx | N1 24.6, N2 23.8 | Cepheid GeneXpert† |
| Day 17: 18 April 2020 | Positive | Nasopharynx | N1 29.2, N2 30.0 | Yale CDC laboratory developed test‡ |
| Day 43: 14 May 2020 | Negative | Nasopharynx | Not applicable | Panther TMA§ |
| Day 46: 17 May 2020 | Positive | Nasopharynx | N2 40, E 0.0 | Cepheid GeneXpert† |
| Day 49: 20 May 2020 | Negative | Nasopharynx | Not applicable | Yale CDC laboratory developed test‡ |
| Day 51: 22 May 2020 | Negative | Nasopharynx | Not applicable | Panther TMA§ |
| Day 56: 27 May 2020 | Negative | Nasopharynx | Not applicable | Thermo Fisher¶ |
| Day 108: 17 July 2020 | Negative | Nasopharynx | Not applicable | Cepheid GeneXpert† |
| Day 129: 6 August 2020 | Positive | Nasopharynx | N2 38.4, E 35.4 | Cepheid GeneXpert† |
| Day 144: 20 August 2020 | Positive | Nasopharynx | N2 43.1, E 0 | Cepheid GeneXpert† |
| Day 148: 24 August 2020** | Negative | Nasopharynx | Not applicable | Panther TMA§ |
| Day 154: 30 August 2020 | Negative | Nasopharynx | Not applicable | Cepheid GeneXpert† |
*Mayo Clinic Laboratories, Rochester, Minnesota, USA
†Cepheid, Sunnyvale, California, USA.
‡Yale Virology Lab, New Haven, Connecticut, USA.
§Hologic, San Diego, California, USA.
¶Thermo Fisher Scientific, Waltham, Massachusetts, USA.
**Received remdesivir on 24–30 August 2020.
E, SARS-CoV-2 E gene; N1, SARS-CoV-2 Nucleocapsid gene 1; N2, SARS-CoV-2 Nucleocapsid gene 2; ORF1a, SARS-CoV-2 Open Reading frame 1a gene.